Completed Access to Information Requests

Transitional Period

Federal departments are moving their web content to Canada.ca. As a part of that process, proactive disclosure reports will become available through the Open Government portal.  During this transition, if a proactive disclosure report from a specific department is not yet available on the Open Government portal please refer to Proactive disclosure by department or agency where a copy can be found.  For any questions on this issue, please contact us at open-ouvert@tbs-sct.gc.ca .

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests previously made to the Government of Canada. If you find a summary of interest, you can request a copy of the records at no cost. For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator.

Enter keywords (e.g. institution, topic, field of interest, etc.)
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Found 3900 record(s)

Req # A-2020-004

Please provide briefing notes prepared for Pierre Lavallée, president and CEO from June 1, 2018 to present.

Organization: Canada Infrastructure Bank

266 page(s)
August 2019

Req # A-2020-005

1) Provide reports, memos, briefings, internal and external meetings held on potential Canada Infrastructure Bank funded projects. 2) Provide reports, including non compliance reports and corrective actions on initial Canada Infrastructure Bank projects. 3) Provide administration budget and cost estimates for the bank, its board, executives and staff, and its rental costs and its operations. Include special benefits and bonuses. 4) Provide other records released or to be released under ATIP.

Organization: Canada Infrastructure Bank

276 page(s)
August 2019

Req # ATI2020-007

The list of reports, memos, etc., that would provide the CEO of BDC with a picture of the essential information that is required for them to oversee BDC Capital from April to May of 2019.

Organization: Business Development Bank of Canada

2 page(s)
July 2019

Req # A-2020-006

Briefing notes provided by Infrastructure Canada to Janice Fukakusa, chair of the Canada Infrastructure Bank's Board of Directors from June 1, 2018 to Present.

Organization: Canada Infrastructure Bank

0 page(s)
July 2019

Req # A-2019-000010

Adverse Reaction Report (AER) for SARILUMAB. Report number: E2B_01396966.

Organization: Health Canada

16 page(s)
July 2019

Req # A-2016-000133

All calendar records for all EX category personnel with Health Canada’s Tobacco Directorate from January 1, 2010 to December 31, 2010.

Organization: Health Canada

2236 page(s)
July 2019

Req # A-2018-001915

Adverse Reaction Report (AER). Report numbers: 0007190167, 000719315, E2B_02165440, 0007197649, E2B_0214262310.

Organization: Health Canada

50 page(s)
July 2019

Req # A-2016-000329

All records for 2015-2016: violation investigations reports on pesticide companies; summary of suspended, delisted and fined pesticide companies; summary of acute pesticide poisoning incidents; surveys on pesticide use and impacts. 2016 briefing notes on concerns with pesticide use.

Organization: Health Canada

1361 page(s)
July 2019

Req # A-2016-001246

All notifiable changes relating to Actavis Pharma Company’s ACT Tadalafil product, Drug Identification Number (DINs) 02428628, 02428636, 02428644, 02428652.

Organization: Health Canada

909 page(s)
July 2019

Req # A-2017-000510

The various versions of the research protocol for the study "A phase I/Ila Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects". The identification number for the clinical trial is NCT01628471.

Organization: Health Canada

59 page(s)
July 2019